TYR and alkaptonuria: The development of NIT as a therapy for AKU was carried out in the phase 3 randomised clinical study SONIA 2 (Suitability Of Nitisinone In Alkaptonuria 2) and provided an opportunity to understand whether the maladaptations in the PHE/TYR pathway resulted in those patients experiencing corneal keratopathies [18].